OverviewSuggest Edit

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. The Company is focused on delivering new therapies to the patients living with chronic skin conditions. The company’s product candidates include Glycopyrronium tosylate, Olumacostat glasaretil and lebrikizumab, which are designed to target primary axillary hyperhidrosis, sebum production, acne vulgaris and other dermatologic diseases.

TypePublic
Founded2011
HQMenlo Park, CA, US
Websitedermira.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2018)333(+106%)
Revenue (FY, 2018)$42.3 M(+88%)
Share Price (Feb 2020)$18.8
Cybersecurity ratingBMore

Key People/Management at Dermira

Bill Aurora

Bill Aurora

Chief Scientific Affairs Officer
Virginia Finnerty-Brooks

Virginia Finnerty-Brooks

Chief Business Officer, SVP
Andrew Hotchkiss

Andrew Hotchkiss

Chief Executive Officer
Delphine Imbert

Delphine Imbert

Senior Vice President, Pharmaceutical Sciences
Gary Thompson

Gary Thompson

Vice President, Compliance Officer
Tracy Vandenberg

Tracy Vandenberg

Vice President, Head of Human Resources
Show more

Dermira Office Locations

Dermira has an office in Menlo Park
Menlo Park, CA, US (HQ)
275 Middlefield Rd #150
Show all (1)

Dermira Financials and Metrics

Dermira Revenue

Dermira's revenue was reported to be $42.34 m in FY, 2018
USD

Revenue (Q3, 2019)

11.5m

Gross profit (Q3, 2019)

9.6m

Gross profit margin (Q3, 2019), %

83.2%

Net income (Q3, 2019)

(57.6m)

EBIT (Q3, 2019)

(55.2m)

Market capitalization (20-Feb-2020)

1.0b

Closing stock price (20-Feb-2020)

18.8

Cash (30-Sept-2019)

74.9m

EV

959.3m
Dermira's current market capitalization is $1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

7.3m22.6m42.3m

Revenue growth, %

208%

Cost of goods sold

1.2m

Gross profit

41.2m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

7.3m39.1m717.0k2.5m66.6m11.5m

Cost of goods sold

237.0k926.0k1.3m1.9m

Gross profit

480.0k1.5m65.3m9.6m

Gross profit Margin, %

67%62%98%83%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

55.4m107.2m41.8m295.9m105.0m

Accounts Receivable

18.8m52.0k5.7m

Prepaid Expenses

5.6m8.3m

Inventories

1.0m2.5m10.6m8.4m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

50.8m52.1m32.7m120.3m92.4m211.0m55.7m201.9m418.3m393.6m288.6m176.3m145.0m201.7m103.2m74.9m

Accounts Receivable

25.0m57.0k56.0k2.1m8.5m59.8m11.1m

Prepaid Expenses

569.0k2.0m2.1m1.9m3.9m5.5m6.6m8.0m7.9m7.8m6.2m10.2m9.3m33.4m25.9m19.8m

Inventories

102.0k2.9m13.4m17.6m23.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(31.9m)(78.4m)(7.4m)(303.3m)(221.5m)

Depreciation and Amortization

47.0k72.0k123.0k339.0k555.0k

Inventories

(572.0k)(1.2m)(6.8m)(8.4m)

Accounts Payable

3.2m3.6m4.3m1.5m823.0k
USDQ3, 2014

Financial Leverage

-0.8 x
Show all financial metrics

Dermira Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Dermira Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Dermira Online and Social Media Presence

Embed Graph

Dermira News and Updates

Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®

The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of age and older is Journey Medical’s seventh marketed dermatology product The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people …

Lilly Completes Acquisition of Dermira

INDIANAPOLIS, Feb. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational,...

Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition

INDIANAPOLIS, Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2019. $ in millions, except per share data Fourth Quarter % Full Year % 2019 2018 Change 2019 2018 Change Revenue $ 6,114.0 $ 5,637.6 8%...

UPDATE 2-Eli Lilly adds eczema drug with $1.1 bln deal for Dermira

Eli Lilly and Co said on Friday it would buy skin disease specialist Dermira Inc for about $1.1 billion in cash, bolstering its arsenal with an experimental therapy for skin disease atopic dermatitis.

(DERM) Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price?

SAN DIEGO, Jan. 10, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dermira, Inc. (NASDAQ: DERM) ("Dermira") breached their fiduciary duties in connection with the proposed sale of the Company to Eli...

Eli Lilly to buy skin-focused biopharma Dermira for $1.1 billion

Eli Lilly to buy skin-focused biopharma Dermira for $1.1 billion
Show more

Dermira Blogs

Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update Content Import Wed, 08/07/2019 - 16:05 Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update August 7, 2019 at 4:05 PM EDT This release is a backf…

Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019

Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019 Content Import Wed, 07/31/2019 - 16:06 Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019 July 31, 2019 at 4:05 PM EDT …

Dermira to Present at the Raymond James Life Sciences and MedTech Conference

MENLO PARK, Calif. --(BUSINESS WIRE)--Jun. 11, 2019-- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced

Dermira to Present at the 18th Annual Needham Healthcare Conference

Dermira to Present at the 18th Annual Needham Healthcare Conference Content Import Wed, 04/03/2019 - 16:07 Dermira to Present at the 18th Annual Needham Healthcare Conference April 3, 2019 at 4:05 PM EDT This release is a backfill from a News Wire …

Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis johncarlo.ong@… Mon, 03/18/2019 - 07:06 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis March 1…

Dermira to Present at the Cowen and Company 39th Annual Health Care Conference

Dermira to Present at the Cowen and Company 39th Annual Health Care Conference Content Import Tue, 03/05/2019 - 16:03 Dermira to Present at the Cowen and Company 39th Annual Health Care Conference March 5, 2019 at 4:00 PM EST This release is a backfill from a …
Show more

Dermira Frequently Asked Questions

  • When was Dermira founded?

    Dermira was founded in 2011.

  • Who are Dermira key executives?

    Dermira's key executives are Bill Aurora, Virginia Finnerty-Brooks and Andrew Hotchkiss.

  • How many employees does Dermira have?

    Dermira has 333 employees.

  • What is Dermira revenue?

    Latest Dermira annual revenue is $42.3 m.

  • What is Dermira revenue per employee?

    Latest Dermira revenue per employee is $127.1 k.

  • Who are Dermira competitors?

    Competitors of Dermira include Alembic Pharmaceuticals, Cipla and PPD.

  • Where is Dermira headquarters?

    Dermira headquarters is located at 275 Middlefield Rd #150, Menlo Park.

  • Where are Dermira offices?

    Dermira has an office in Menlo Park.

  • How many offices does Dermira have?

    Dermira has 1 office.